The UK-based company, founded in 2002, offers drugs for the treatment of atrial fibrillation, overactive bladder, pain, and autoimmune diseases. Xention Limited's drug candidates modulate two novel but well-characterized ion channels to create breakthrough products in an area of significant unmet medical need. The company's mission is to improve the treatment of atrial fibrillation by developing novel therapies that can be used by the healthcare industry.